Updated event information for the 23rd Planova™ Workshop
The information about The 23rd Planova™ Workshop has been updated.
Please check the PDF file below for the 2nd announcement.
Register to attend The 23rd Planova Workshop
Updated event information for the 23rd Planova™ Workshop
The information about The 23rd Planova™ Workshop has been updated.
Please check the PDF file below for the 2nd announcement.
Register to attend The 23rd Planova Workshop
Learn about Planova™ Workshops and Seminars. Find opportunity to share experiences and to learn the best practices about virus filtration. asahi Kasei Bioprocess - Pioneering Biologics Safety and Manufacturing Efficiency.
The 23rd Planova™ Workshop
Further to our 1st announcement in May, we are pleased to give you more information on the upcoming 23rd Planova™ Workshop held in the heart of Manhattan, New York.
asahi Kasei Medical Co., Ltd.
asahi Kasei Medical Corporation is pleased to announce that research findings of the blocking model theory elucidated a more rigorous verification of the filtration behavior of "Planova™" virus removal filter.
asahi Kasei Medical is the global market leader in virus filtration, with its "Planova™" having an unrivaled 30-year history of trusted use in the production of biotherapeutics. We aim to provide "assurance Beyond Expectation" to ensure product safety and manufacturing efficiency for therapeutics within the biopharmaceutical industry in the form of innovative yet exceptionally reliable purification consumables, equipment and support services.
Relocation of asahi Kasei Bioprocess Office in Brussels
We wish to inform you that the asahi Kasei Bioprocess Europe office in Brussels address has relocated to new premises effective 1st June 2022; our new address is:
asahi Kasei Bioprocess Europe S.a./N.V.
Boulevard auguste Reyers 70
about asahi Kasei Bioprocess
Our Business OverviewOur Global NetworkOur History
Pioneering Biologics Safety and Manufacturing Efficiency
asahi Kasei Medical Completes acquisition of Bionova Scientific, U.S.-based biopharmaceutical CDMO
asahi Kasei Medical Co., Ltd.
asahi Kasei Medical has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies as announced on april 19, 2022. The acquisition closed on May 31, 2022 (US Pacific time).
Bionova Scientific will operate as a business unit within asahi Kasei Medical's Bioprocess Division, and Darren Head, the current CEO of Bionova Scientific, will continue to lead the company. Bionova Scientific will continue to expand its business by building on its strengths as a CDMO specialized in the process design and manufacture of various types of biologics that are particularly difficult to develop. Moving forward, asahi Kasei Medical aims to provide biopharmaceutical companies with further added value and higher customer satisfaction by leveraging its existing bioprocess consumables, equipment and biosafety testing services businesses together with Bionova Scientific's biologics CDMO business.
Filtration Procedure: Planova™ 15N, 20N, 35N and 75N Filters
Integrity Test Procedure Planova™ 15N, 20N and 35N Filters: Liquid Forward-Flow Rate (LFR) Test